➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Johnson and Johnson
Mallinckrodt
Express Scripts
Harvard Business School

Last Updated: September 25, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZORTRESS

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Zortress

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00419159 ↗ Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy Completed Novartis Pharmaceuticals Phase 2 2006-12-01 To assess the safety and efficacy of weekly (70 mg per week) and daily (10 mg per day) everolimus in patients with metastatic colorectal cancer whose cancer has progressed despite prior treatment with targeted therapy and chemotherapy.
NCT00622869 ↗ Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients Completed Novartis Pharmaceuticals Phase 3 2008-01-01 This trial was designed to address important issues that impact recipients of liver allografts as well as clinicians, ie, renal function, reduction or discontinuation of tacrolimus early post-transplantation, and progression rate of fibrosis in hepatitis C virus (HCV) positive patients.
NCT00651482 ↗ Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus) Terminated Genentech, Inc. Phase 2 2008-08-01 To determine the safety and efficacy of the combination of bevacizumab and everolimus (RAD001) for the treatment of metastatic renal cell cancer
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zortress

Condition Name

Condition Name for Zortress
Intervention Trials
Liver Transplantation 3
Breast Cancer 3
Renal Transplant 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zortress
Intervention Trials
Carcinoma 8
Neoplasms 7
Carcinoma, Renal Cell 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zortress

Trials by Country

Trials by Country for Zortress
Location Trials
United States 210
Italy 11
Canada 8
Spain 6
Brazil 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zortress
Location Trials
Texas 18
California 13
Ohio 9
Illinois 8
New York 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zortress

Clinical Trial Phase

Clinical Trial Phase for Zortress
Clinical Trial Phase Trials
Phase 4 8
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zortress
Clinical Trial Phase Trials
Recruiting 21
Not yet recruiting 12
Active, not recruiting 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zortress

Sponsor Name

Sponsor Name for Zortress
Sponsor Trials
M.D. Anderson Cancer Center 14
National Cancer Institute (NCI) 13
Novartis Pharmaceuticals 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zortress
Sponsor Trials
Other 54
Industry 30
NIH 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Johnson and Johnson
McKinsey
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.